Anti-IL6RA/ IL6R/ CD126 monoclonal antibody

Anti-IL6RA/ IL6R/ CD126 antibody for FACS & in-vivo assay

Target products collectionGo to IL6R/IL6R products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-TA027-Ab-1/ GM-Tg-hg-TA027-Ab-2Anti-Human IL6R monoclonal antibodyHuman
GM-Tg-rg-TA027-Ab-1/ GM-Tg-rg-TA027-Ab-2Anti-Rat IL6R monoclonal antibodyRat
GM-Tg-mg-TA027-Ab-1/ GM-Tg-mg-TA027-Ab-2Anti-Mouse IL6R monoclonal antibodyMouse
GM-Tg-cynog-TA027-Ab-1/ GM-Tg-cynog-TA027-Ab-2Anti-Cynomolgus/ Rhesus macaque IL6R monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-TA027-Ab-1/ GM-Tg-felg-TA027-Ab-2Anti-Feline IL6R monoclonal antibodyFeline
GM-Tg-cang-TA027-Ab-1/ GM-Tg-cang-TA027-Ab-2Anti-Canine IL6R monoclonal antibodyCanine
GM-Tg-bovg-TA027-Ab-1/ GM-Tg-bovg-TA027-Ab-2Anti-Bovine IL6R monoclonal antibodyBovine
GM-Tg-equg-TA027-Ab-1/ GM-Tg-equg-TA027-Ab-2Anti-Equine IL6R monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-TA027-Ab-1/ GM-Tg-hg-TA027-Ab-2; GM-Tg-rg-TA027-Ab-1/ GM-Tg-rg-TA027-Ab-2;
GM-Tg-mg-TA027-Ab-1/ GM-Tg-mg-TA027-Ab-2; GM-Tg-cynog-TA027-Ab-1/ GM-Tg-cynog-TA027-Ab-2;
GM-Tg-felg-TA027-Ab-1/ GM-Tg-felg-TA027-Ab-2; GM-Tg-cang-TA027-Ab-1/ GM-Tg-cang-TA027-Ab-2;
GM-Tg-bovg-TA027-Ab-1/ GM-Tg-bovg-TA027-Ab-2; GM-Tg-equg-TA027-Ab-1/ GM-Tg-equg-TA027-Ab-2
Products NameAnti-IL6R monoclonal antibody
Formatmab
Target NameIL6R
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IL6R benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-507Pre-Made Sarilumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody
    BiosimilarGMP-Bios-ab-308Pre-Made Levilimab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody
    BiosimilarGMP-Bios-ab-509Pre-Made Satralizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody
    BiosimilarGMP-Bios-ab-584Pre-Made Tocilizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody
    BiosimilarGMP-Bios-ab-625Pre-Made Vobarilizumab biosimilar, Bispecific Single Domains (VH-VH'), Anti-IL6R;ALB Antibody: Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody
    BiosimilarGMP-Bios-ab-506Pre-Made Sapelizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species IL6RA/ IL6R/ CD126 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-TA027-Ag-1Interleukin 6 receptor (IL6R) protein
    ORF Viral VectorvGMLP000774human IL6R Lentivirus particle
    ORF Viral VectorpGMLP000774human IL6R Lentivirus plasmid
    ORF Viral VectorpGMLPm002017mouse Il6ra Lentivirus plasmid
    ORF Viral VectorvGMLPm002017mouse Il6ra Lentivirus particle


    Target information

    Target IDGM-TA027
    Target NameIL6R
    Gene ID3570,16194,24499,716690,612271,101085689,507359,102148787
    Gene Symbol and SynonymsCD126,gp80,HIES5,IL-1Ra,IL-6R,IL-6R-1,IL-6R-alpha,IL-6RA,IL6Q,IL6QTL,IL6R,IL6R1,IL6RA,IL6RQ
    Uniprot AccessionP08887,P22273
    Uniprot Entry NameIL6RA_HUMAN,IL6RA_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseOvary Cancer, myeloma patients
    Gene EnsemblENSG00000160712
    Target ClassificationCheckpoint-Immuno Oncology

    The target: IL6R, gene name: IL6R, also named as CD126, IL-6R-1, IL-6RA, IL6QA, IL6RQ, gp80, IL6R. This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been identified in this gene. A pseudogene of this gene is found on chromosome 9. [provided by RefSeq, Aug 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.